Drug Interactions between dexmethylphenidate and trandolapril
This report displays the potential drug interactions for the following 2 drugs:
- dexmethylphenidate
- trandolapril
Interactions between your drugs
trandolapril dexmethylphenidate
Applies to: trandolapril and dexmethylphenidate
MONITOR: Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs or agents with hypotensive properties. According to serdexmethylphenidate label information, CNS stimulants cause a mean increase in blood pressure of approximately 2 to 4 mmHg and a mean increase in heart rate of approximately 3 to 6 beats per minute. With some individuals having larger increases.
MANAGEMENT: Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as: potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists. The dosage of the antihypertensive drug should be adjusted as needed.
References (8)
- (2001) "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals
- (2022) "Product Information. Metadate CD (methylphenidate)." Celltech Pharmaceuticals Inc
- (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
- (2002) "Product Information. Metadate ER (methylphenidate)." Celltech Pharmaceuticals Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2013) "Product Information. Ritalin LA (methylphenidate)." Quality Care Products/Lake Erie Medical
- (2021) "Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate)." Corium, Inc.
Drug and food interactions
trandolapril food
Applies to: trandolapril
GENERALLY AVOID: Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors. In some cases, affected patients were using a potassium-rich salt substitute. ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.
MANAGEMENT: It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake. Particular attention should be paid to the potassium content of salt substitutes.
References (3)
- (2002) "Product Information. Vasotec (enalapril)." Merck & Co., Inc
- Good CB, McDermott L (1995) "Diet and serum potassium in patients on ACE inhibitors." JAMA, 274, p. 538
- Ray K, Dorman S, Watson R (1999) "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens, 13, p. 717-20
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.